Advertisement

Topics

Sanofi and Ablynx Link on Nanobody Therapeutics

08:46 EDT 4 Aug 2017 | CHEManager

French drugmaker Sanofi has signed a research and licensing deal with Belgian biopharmaceutical company Ablynx, initially focusing on the development and commercialization of Nanobody-based therapeutics for treating various immune-mediated inflammatory diseases.

Original Article: Sanofi and Ablynx Link on Nanobody Therapeutics

NEXT ARTICLE

More From BioPortfolio on "Sanofi and Ablynx Link on Nanobody Therapeutics"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...